000859196 001__ 859196
000859196 005__ 20210130000209.0
000859196 0247_ $$2doi$$a10.1093/neuonc/noz003
000859196 0247_ $$2ISSN$$a1522-8517
000859196 0247_ $$2ISSN$$a1523-5866
000859196 0247_ $$2altmetric$$aaltmetric:53509404
000859196 0247_ $$2pmid$$apmid:30615138
000859196 0247_ $$2WOS$$aWOS:000473768600005
000859196 037__ $$aFZJ-2019-00086
000859196 082__ $$a610
000859196 1001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b0$$eCorresponding author$$ufzj
000859196 245__ $$aPET Imaging in Patients with Brain Metastasis - Report of the RANO/PET Group
000859196 260__ $$aOxford$$bOxford Univ. Press$$c2019
000859196 3367_ $$2DRIVER$$aarticle
000859196 3367_ $$2DataCite$$aOutput Types/Journal article
000859196 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1557995766_28761
000859196 3367_ $$2BibTeX$$aARTICLE
000859196 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000859196 3367_ $$00$$2EndNote$$aJournal Article
000859196 520__ $$aBrain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and surgical resection. The use of systemic treatment for intracranial disease control also is improving. BM diagnosis, treatment planning, and follow-up is most often based on contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging modalities including standard MRI have limitations in accurately characterizing posttherapeutic reactive changes and treatment response. Molecular imaging techniques such as positron emission tomography (PET) characterize specific metabolic and cellular features of metastases, potentially providing clinically relevant information supplementing anatomic MRI. Here, the Response Assessment in Neuro-Oncology working group provides recommendations for the use of PET imaging in the clinical management of patients with BM based on evidence from studies validated by histology and/or clinical outcome.
000859196 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000859196 588__ $$aDataset connected to CrossRef
000859196 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b1$$ufzj
000859196 7001_ $$0P:(DE-HGF)0$$aAlbert, Nathalie L$$b2
000859196 7001_ $$0P:(DE-HGF)0$$aChamberlain, Marc$$b3
000859196 7001_ $$0P:(DE-HGF)0$$aSoffietti, Riccardo$$b4
000859196 7001_ $$0P:(DE-HGF)0$$aKim, Michelle M$$b5
000859196 7001_ $$0P:(DE-HGF)0$$aLaw, Ian$$b6
000859196 7001_ $$0P:(DE-HGF)0$$aLe Rhun, Emilie$$b7
000859196 7001_ $$0P:(DE-HGF)0$$aChang, Susan$$b8
000859196 7001_ $$0P:(DE-HGF)0$$aSchwarting, Julian$$b9
000859196 7001_ $$0P:(DE-HGF)0$$aCombs, Stephanie E$$b10
000859196 7001_ $$0P:(DE-HGF)0$$aPreusser, Matthias$$b11
000859196 7001_ $$0P:(DE-HGF)0$$aForsyth, Peter$$b12
000859196 7001_ $$0P:(DE-HGF)0$$aPope, Whitney$$b13
000859196 7001_ $$0P:(DE-HGF)0$$aWeller, Michael$$b14
000859196 7001_ $$0P:(DE-HGF)0$$aTonn, Jörg C$$b15
000859196 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noz003$$n5$$p585-595$$tNeuro-Oncology$$v21$$x1523-5866$$y2019
000859196 8564_ $$uhttps://juser.fz-juelich.de/record/859196/files/noz003.pdf$$yRestricted
000859196 8564_ $$uhttps://juser.fz-juelich.de/record/859196/files/noz003.pdf?subformat=pdfa$$xpdfa$$yRestricted
000859196 909CO $$ooai:juser.fz-juelich.de:859196$$pVDB
000859196 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b0$$kFZJ
000859196 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b1$$kFZJ
000859196 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000859196 9141_ $$y2019
000859196 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000859196 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2017
000859196 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000859196 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000859196 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000859196 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000859196 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000859196 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000859196 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000859196 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000859196 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2017
000859196 920__ $$lyes
000859196 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000859196 980__ $$ajournal
000859196 980__ $$aVDB
000859196 980__ $$aI:(DE-Juel1)INM-3-20090406
000859196 980__ $$aUNRESTRICTED